Cellectar Biosciences CLRB 深 滬
等待開盤 08-14 09:30:00 美东时间
4.42
-0.190
-4.12%
華盛通- 最 高4.68
- 今 開4.65
- 成交量 12.27万股
- 最 低 4.38
- 昨 收 4.61
- 總市值 2.04亿
- 52周最高 68.70
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 4.36
- 委 比 -95.78%
- 總股本 4607.99万
- 歷史最高 276000.00
- 量 比 2.04
- 振 幅 6.51%
- 歷史最低 4.38
- 每 手 1
- 風險率 24.58%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多A Peek at Cellectar Biosciences's Future Earnings
Cellectar Biosciences (NASDAQ:CLRB) is preparing to release its quarterly earni...
今天 00:03
Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 14, 2025
Cellectar Biosciences Inc. will release its Q2 2025 financial results and provide a corporate update on August 14, 2025, at 8:30 a.m. ET. The conference call includes a toll-free number (1-800-717-1738) and a webcast link. Cellectar focuses on developing cancer treatments using its Phospholipid Drug Conjugate™ (PDC) platform, with key programs like iopofosine I 131, CLR 121225, and CLR 121125 in clinical trials, receiving multiple FDA designation...
08-07 12:05
CLEAR is Under Construction in Epic Toolbox in Identity Verification for EpicCare Link to Streamline Provider Access, Boost Security
CLEAR is integrating its identity verification platform with Epic's EpicCare Link, aiming to enhance account creation and recovery workflows for healthcare providers. This integration, set to support community-based healthcare systems, will streamline processes, reduce administrative burdens, and improve security. CLEAR also plans to expand its integration into MyChart by November 2025, further solidifying its role as a secure identity layer in h...
08-07 10:00
CLEAR Joins White House and CMS Effort to Power an Interoperable, Secure Digital Health Ecosystem
CLEAR, a secure identity platform, is collaborating with the Centers for Medicare & Medicaid Services (CMS) in a nationwide initiative to modernize healthcare through interoperable technologies. As an Identity Assurance Level 2 (IAL2)/Authenticator Assurance Level 2 (AAL2) identity layer, CLEAR supports a connected, patient-centered healthcare system. Its reusable identity platform, CLEAR1, enables seamless access to medical records, simplifies p...
07-31 22:48
CLEAR, an Official TSA PreCheck® Enrollment Provider, Expands Enrollment and Renewal Options by Opening a New Location at Aventura Mall in South Florida
CLEAR has launched a new TSA PreCheck enrollment location at Aventura Mall in Florida, offering consumers an additional convenient option to enroll or renew their Trusted Traveler program membership. This new location complements CLEAR's existing 62 airport-based enrollment points across the U.S. and reflects the company's ongoing expansion strategy. The new site is open Monday through Saturday from 11 a.m. to 7 p.m. ET and Sunday from noon to 7 ...
07-24 10:00
Cellectar Biosciences Has Been Granted European Patent Number EP3773544 Titled "PHOSPHOLIPID-FLAVAGLINE CONJUGATES AND METHODS OF USING THE SAME FOR TARGETED CANCER THERAPY".
https://data.epo.org/publication-server/publications/pdf?path=2025/30/DOC/EPNWB1/EP19784548NWB1/EP19784548NWB1.pdf
07-24 03:58
CLEAR to Provide Discounted TSA PreCheck® for Military Families
CLEAR is participating in TSA's initiative to offer discounted or free TSA PreCheck enrollment for military spouses and Gold Star families. Currently serving military spouses receive a $25 discount, while Gold Star families get free enrollment. CLEAR is also bringing mobile enrollment units to military installations to ease access. TSA PreCheck allows members to keep shoes, belts, and light jackets on during security checks and store laptops and ...
07-10 10:00
Cellectar Biosciences Announces Closing of $6.9 Million Underwritten Public Offering, including Full Exercise of Over-Allotment Option
Cellectar Biosciences announced the closing of an underwritten public offering raising approximately $6.9 million. The offering included Class A and Class B Units, with proceeds to support general corporate purposes and initiate a Phase 1b study for CLR 125 in triple-negative breast cancer. The securities were registered with the SEC, and Ladenburg Thalmann acted as sole bookrunning manager.
07-02 20:15
CareCloud Joins Russell Microcap Index as Common Stock Price Rises 70% During Q2 2025
CareCloud,Inc., a leader in AI-driven healthcare technology solutions, has been added to the Russell Microcap® Index, effective June 30, 2025. This inclusion reflects growing recognition of the company's momentum in the healthcare technology sector. During Q2 2025, the company's stock price increased by approximately 70%, driven by key developments including the launch of its new AI Center of Excellence, resumption of acquisition activities, and ...
07-02 12:00
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Neurogene (NASDAQ:NGNE) shares increased by 32.3% to $19.77 during Tue...
07-02 01:05
